Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and ...

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and ...

KORU Medical Systems, Inc. KRMD has made a strategic move in its pursuit of expanding its footprint in the realm of large-volume subcutaneous infusion. The company announced a collaboration with a ...

Please provide your email address to receive an email when new articles are posted on . 52-week study included 85 adults with Parkinson’s and at least 3 hours/day of “off” time. At week 12, CSAI led ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said a subcutaneous (under the skin) formulation of Tecentriq showed to be as good as an intravenous (IV) infusion of the drug in a study consisting of ...

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and ...

Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment. Joshua K. Sabari, MD, director of High Reliability Organization ...